Farhad Hafezi

Farhad Hafezi is a prominent Swiss eye surgeon and researcher.

Hafezi was born in Remscheid, Germany in 1967, but he moved to Fribourg in Switzerland in 1981.

Hafezi has published almost 200 articles in various peer-reviewed scientific journals since 1993, including Nature Medicine, Nature Genetics, Investigative Ophthalmology & Visual Science (IOVS), the Journal of Refractive Surgery, and Cell Death & Differentiation.

His work in the field of corneal collagen cross-linking has led him to receive a number of international awards.

He studied medicine in Fribourg and Bern, obtaining his Doctorate of Medicine at the Inselspital Bern under Prof. Dr. med Peter Weidmann, before going on in 1993, to undertake a two-year postgraduate course in Experimental Medicine and Biology at the University of Zürich.

Hafezi spent three additional years at the University Hospital of Zurich, where he worked in the Laboratory for Retinal Cell Biology, which was part of the Department of Ophthalmology.

Whilst studying in the Zürich laboratory, Hafezi identified the first known gene, c-Fos, that the absence of which could completely suppress light-induced apoptotic retinal degeneration.

Hafezi first gained recognition as a leading retina researcher in 1994, having been the first to discover a gene responsible for light-induced retinal degeneration.

The group's findings were featured on the cover of the April 1997 edition of Nature Medicine.

Hafezi then focused on a number of areas of cellular and retinal degeneration, in particular, light-induced photoreceptor death in the absence of p53 and JunD/AP-1, work that was published in IOVS and Cell Death & Differentiation, respectively.

c-Fos and Fra1 are both components of the transcription factor AP-1, and in the year 2000, Hafezi and his colleagues presented work that showed that, in genetically engineered mice that express Fra1 where c-Fos is usually expressed, Fra1 can function in lieu of c-Fos to promote light-induced retinal photoreceptor death – work that was published in Genes & Development.

That same year, Hafezi was part of a research group that identified the visual cycle enzyme RPE65 as essential component of light-induced retinal degeneration.

The article was published in Nature Genetics.

In 2001, his work investigating the molecular pathways that underpin light-induced retinal photoreceptor apoptosis continued with a paper published in Cell Death & Differentiation showing that AP-1 mediated retinal photoreceptor apoptosis was independent of N-terminal phosphorylation of one of its components, c-Jun.

Later that year, he and a team of researchers utilized a mouse strain with a single base change in codon 450 of the RPE65 gene (the Leu450Met variation) in which RPE65 regenerates rhodopsin at a far slower rate than wild-type animals; this mutation was observed to increase retinal resistance against light-induced degeneration, and demonstrating that the light damage susceptibility of the retina is tied to rhodopsin regeneration kinetics.

In 2002, Hafezi's clinical and research interests turned to the cornea.

He became a corneal specialist, and his work helped develop the principles of corneal collagen cross-linking (CXL) and translate CXL from a laboratory into a clinical setting, initially for the treatment of keratoconus.

Hafezi's combination of basic science knowledge combined with clinical, surgical experience of CXL has led him to become one of the world's leading experts on both keratoconus and cross-linking technology.

The impact of CXL on the treatment of keratoconus is hard to underestimate: today, CXL considered to be the treatment of choice for progressive keratoconus and corneal ectasias, reducing the need for corneal transplantation by half.

Hafezi continued to work to expand the number of people who could benefit from CXL.

Briefly, the original CXL method, termed the Dresden Protocol, involves removing the central 8–10 mm of the corneal epithelium of adult patients with corneas thicker than 400 µm, and applying 0.1% riboflavin solution to the cornea for 30 minutes before, and at 5-minute intervals during 365 nm UV-A irradiation of the corneal surface at an irradiance of 3 mW/cm2.

Hafezi has helped push the boundaries, pioneering CXL in children with keratoconus, the use of hypoosmolar riboflavin solutions to treat people with thin (≤400 µm) corneas.

and using CXL to treat post-LASIK ectasia.

The knowledge Hafezi accrued from this work led to him becoming a leading international expert on corneal ectasia in general and keratoconus in particular.

His expertise in treating children with keratoconus using CXL has led to his involvement in shaping safety standards and best practice models for treatment.

Hafezi has implemented other CXL treatments in more recent times.

The keratoconus treatment via pediatric application and also using CXL principles for treating infectious keratitis.

Hafezi also hold two medical patents, both related to CXL technology and treatments.

Hafezi has won a number of international awards due to his contributions in the advancement of CXL technology and its applications, including:

However, he changed his research focus to the cornea in 2003, and it is this work, particularly on corneal collagen cross-linking (CXL), which he helped pioneer, and advanced laser refractive surgery that he is internationally known for today.

Hafezi's current clinical and laboratory research is focused on gaining a better understanding of the cornea.

His research group at the University of Zurich has three main research foci:

Hafezi is considered to be a leading expert and key opinion leader in the development and translation of CXL and its multiple applications in the field of ophthalmology, including the treatment of corneal ectatic disorders like keratoconus, pellucid marginal degeneration and post-LASIK ectasia.

Hafezi and his colleagues have also pioneered the use of CXL for the treatment of corneal infections, calling the technique “photoactivated chromophore for infectious keratitis cross-linking”, or PACK-CXL.

Additionally, in 2012, Hafezi and his colleague, Dr. Olivier Richoz, won the University of Geneva's INNOGAP award for the development of a disposable medical device (the C-Eye device) for performing PACK-CXL.

Hafezi is one of the most cited ophthalmologists of his generation, with a h index of 45 and a total more than 7,700 citations in the scientific literature.

1. Corneal collagen cross-linking,   Randleman B, Hafezi F, Editors.

2013, Slack Inc.: Thorofare, NJ, USA.

In 2014, 2016, 2018, 2020 and 2023 his peers ranked Hafezi as one of the top 100 most influential people in ophthalmology.

He is currently a professor of ophthalmology at the University of Geneva, an adjunct clinical professor of ophthalmology at the Keck School of Medicine, University of Southern California, a research group leader of the Ocular Cell Biology Group at the Center for Applied Biotechnology and Molecular Medicine at the University of Zurich, a visiting professor at the University of Wenzhou, China, a research professor of ophthalmology at the NYU Grossman School of Medicine, and medical director of the ELZA Institute.